Zydus Cadila gets USFDA nod for NSAID Diclofenac Sodium

Pharmaceuticals maker Zydus Cadila said it received the final approval from the USFDA to market inflammation solution Diclofenac Sodium in the country.

Diclofenac Sodium topical solution, 1.5%, is a non-steroidal anti-inflammatory drug (NSAID) used for symptomatic treatment of osteoarthritis of the knee.

It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad, the Indian company said.

With this, said Zydus Cadila, it has more than 185 drug approvals out of the 320 generic applications made since 2003-04.

The company develops, manufactures and markets a broad range of healthcare therapies.

It is headquartered at Ahmedabad in Gujarat and employs over 21,000 people worldwide.

It is the fourth largest pharmaceutical company in India.

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi.

In 1995 the Patel and Modi families split, with the Modi family’s share being moved into a new company called Cadila Pharmaceuticals Ltd. and Cadila Healthcare became the Patel family’s holding company.

In 2015, Cadila Healthcare acquired German Remedies.